Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Marseille Cedex 09, France Clinical Trials

A listing of Marseille Cedex 09, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (114) clinical trials

Surgery in Treating Patients With Neuroblastoma

OBJECTIVES: - Evaluate the safety and efficacy of surgical treatment alone for stage II neuroblastoma without N-myc amplification (NMA). - Describe predictive factors of relapse and survival for stages I and II neuroblastoma without NMA treated by surgery alone. OUTLINE: Patients with localized resectable tumors undergo surgery. Postoperative evaluations are ...

Phase

0.0 miles

Learn More »

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: - Determine the 18-month survival rate of patients with metastatic renal cell carcinoma treated with allogeneic stem cell transplantation. - Determine the objective rate of response of patients treated with this regimen. - Determine post-transplant immunological reactions and recuperation of patients treated with this regimen. - Determine the antitumoral ...

Phase

0.0 miles

Learn More »

Immunotherapy by Nivolumab for HIV+ Patients

Two Phase III trials showed superiority in terms of efficacy and tolerance of nivolumab in second-line treatment compared to docetaxel in metastatic NSCLC in the general population, so it is important to evaluate this treatment in PLWHIV (Patient Living With HIV) in maximum security conditions, taking into account their specificities ...

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.

Phase

0.0 miles

Learn More »

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment

The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated second line therapy). The main goal of this study is to evaluate ...

Phase

0.0 miles

Learn More »

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Adult medulloblastoma is a rare tumour. The "standard risk " group (complete surgery or residual tumour lower than 1,5 cm2, absence of malignant cells in the cerebrospinal fluid, absence of metastasis, absence of MYC amplification and exclusion of large cells medulloblastoma) concerns, for the adult population, a majority of patients ...

Phase

0.0 miles

Learn More »

A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent

Two different situations will be considered: in NSMGCT patients treated with cisplatin-based chemotherapy, the objective is to maintain a 2-year progression-free survival rate >80% despite a limitation of the number of course of chemotherapy (4) after the achievement of a clinical and biological response (primary endpoint); in children over 10 ...

Phase

0.0 miles

Learn More »

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.

Phase

0.0 miles

Learn More »

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune ) in the Treatment of Severe Arteriovenous Malformations

Anti-proliferative and anti-angiogenic properties of Sirolimus (Rapamycin) are the basis of the rationale to use it in the treatment of arteriovenous malformations, for which the pathophysiology remains poorly understood. The interest of this class of drug is that inhibition of mTOR (mammalian target of rapamycin) may also block growth and ...

Phase

0.0 miles

Learn More »

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

METHODOLOGY Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 4 cohort: cohort A: Osteosarcoma cohort B: Ewing sarcoma cohort C: Chondrosarcoma cohort D : chondroma. Cohort A, B and C will involve a total of 36 patients (24 Regorafenib + 12 placebo). And cohort D ...

Phase

0.0 miles

Learn More »